InterCure Reschedules 2022 Full Year Results Conference Call
InterCure Ltd (NASDAQ: INCR) has announced a rescheduled conference call to discuss its financial results for the year ending December 31, 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
InterCure Ltd (NASDAQ: INCR) has announced a rescheduled conference call to discuss its financial results for the year ending December 31, 2022. The call will now take place on April 4, 2023, at 4:30 P.M. Eastern time, instead of the originally planned date of April 3. The change was necessitated by unforeseen technical issues. InterCure is noted as the leading and fastest-growing cannabis company outside North America, with its subsidiary, Canndoc, being Israel's largest licensed cannabis producer. The company aims to maintain its position in the rapidly growing global cannabis market.
Positive
- Strength as the leading cannabis company outside North America.
- Canndoc is Israel's largest licensed cannabis producer.
Negative
- Rescheduling of the conference call due to unforeseen technical issues could raise concerns about operational efficiency.
Details
News Market Reaction – INCR
The recorded move for INCR in the trading session of this news was +25.74%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, TORONTO, and HERZLIYA, Israel, April 03, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)("InterCure" or the “Company”) announced today that it has rescheduled its previously announced conference call to discuss the company's financial results for the full year ended December 31, 2022.
The call was originally scheduled for April 3 at 4:30 P.M. (Eastren time) but has been rescheduled to April 4, at 4:30 P.M. (Eastren time) due to unforeseen circumstances which caused technical issues.
Participants can access the live webcast and conference call through the following link:
https://register.vevent.com/register/BIdec7603751894ebcbf0f22eca91cdb4a
About InterCure (dba Canndoc)
InterCure (dba Canndoc) (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) is the leading, profitable, and fastest growing cannabis company outside of North America. Canndoc, a wholly owned subsidiary of InterCure, is Israel’s largest licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products. InterCure leverages its international market leading distribution network, best in class international partnerships and a high-margin vertically integrated "seed-to-sale" model to lead the fastest growing cannabis global market outside of North America.
For more information, visit: http://www.intercure.co.
Contact:
InterCure Ltd.
Amos Cohen, Chief Financial Officer
amos@intercure.co
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.